Navigation Links
Diamyd Strengthens Financial Position and Executes a Fully Subscribed Direct Placement
Date:4/21/2008

STOCKHOLM, Sweden, April 21 /PRNewswire-FirstCall/ -- Diamyd Medical AB (publ) has decided on, and successfully executed, a direct placement of in total 991,000 series B shares. The shares have been placed with a limited group of professional investors at a price of 73 SEK per share. The issue raises 72.3 MSEK in total for the Company before issue costs. For each issued and paid new share one warrant is received free of charge, which gives the right to subscribe for a series B share at a price of 100 SEK during April 2009. Full use of the issued warrants will generate an additional 99.1 MSEK in proceeds to the Company.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 )

(Photo: http://www.newscom.com/cgi-bin/prnh/20080421/301418 )

"This issue takes us one further step towards the commercialization of our therapeutic diabetes vaccine Diamyd(R)," says Elisabeth Lindner, President and CEO of Diamyd Medical. "At the same time as resources are secured for financing of the clinical phase III studies which are needed for market approval, we will now continue our partnership discussions for Diamyd(R) and NTDDS from a position of strength. I am warmly welcoming our new shareholders."

Stockholm Corporate Finance has been financial advisor to Diamyd regarding the issue.

This information is disclosed in accordance with the Securities Markets Act, the Financial Instruments Trading Act or demands made in the exchange rules.

Diamyd Medical is a Swedish biopharmaceutical company focusing on development of pharmaceuticals for treatment of autoimmune diabetes and its complications. The company's most advanced project is the GAD-based drug Diamyd(R) for type 1- diabetes and for which Phase III trials have been initiated in both the US and Europe. Furthermore the company has initiated clinical studies within chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson's disease.

Diamyd Medical has offices in Sweden and in the US. The share is quoted on the OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further information is available on the company's web site: http://www.diamyd.com

For more information, please contact:

Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.), elisabeth.lindner@diamyd.com, Phone: +46-8-661-0026

For pictures and press material, please contact:

Sonja Catani, Chief Communications Officer Diamyd Medical AB (publ.), sonja.catani@diamyd.com, Phone: +46-8-661-00-26


'/>"/>
SOURCE Diamyd Medical AB (publ)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Diamyd Gets Authorization to Begin Phase III Study in the US
2. Medpace Strengthens Presence in Central Europe
3. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
4. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
5. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
6. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
7. Anavex strengthens Board of Directors
8. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. JobLoft.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
11. BioSpace.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... SHELTON, Conn. , Feb. 8, 2016  NanoViricides, Inc. (NYSE ... that its CEO, Eugene Seymour , MD, MPH, will present ... 5:30PM at the Waldorf-Astoria Hotel in New York City ... presentation will be in the Windsor Room at 5:30PM EST. Registered ... New York City . --> ...
(Date:2/8/2016)... --> --> ... Point-Of-Care (POC) molecular diagnostics company, today announces that it has ... to be launched on the Company,s io® platform. By meeting ... is now cleared for sale within the European Union. ... the io® CT test signals a new era in ultra-rapid ...
(Date:2/5/2016)... , Feb. 5, 2016 ATCC, the premier ... to assist the medical and life science researchers that ... Virus infection.   CDC website . ... Zika virus is a single-stranded RNA virus of ... West Nile, Dengue and Chikungunya Viruses. Zika virus is ...
(Date:2/5/2016)... 5, 2016 Amarantus BioScience Holdings, ... focused on developing products for Regenerative Medicine, Neurology and ... Disease Designation (RPDD) from the US Food and Drug ... MANF was previously granted orphan drug designation (ODD) by ... Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), ...
Breaking Biology Technology:
(Date:1/18/2016)... 18, 2016  Extenua Inc., a pioneering developer ... use and access of ubiquitous on-premise and cloud ... American Cyber.  ... transformational C4ISR and Cyber initiatives in support of ... proven technology solutions," said Steve Visconti , ...
(Date:1/11/2016)... Synaptics Incorporated (NASDAQ: SYNA ), the ... its ClearPad ® TouchView ™ 4300 touch ... categories in the 8 th Annual Mobile Excellence ... The Synaptics ® TDDI solution enables faster time-to-market, ... devices, brighter displays and borderless designs. ...
(Date:1/7/2016)... -- This BCC Research report studies the global as ... identifying newer markets and exploring the expansion of the ... Includes forecast from 2015 to 2020. Use ... the expansion of the present application market for various ... technology, determine its current market size, and estimate the ...
Breaking Biology News(10 mins):